Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week Phase 3 studies in patients with moderate to severe plaque psoriasis

被引：0
|
作者：
Kaur, M. [1 ]
Merola, J. [2 ]
Tatulych, S. [3 ]
Mamolo, C. [3 ]
Lan, S. [3 ]
机构：
[1] Pfizer, Collegeville, PA USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Dermatol, Boston, MA USA
[3] Pfizer, Groton, CT USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
psoriasis; nails; tofacitinib;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P157
引用
收藏
页码：81 / 81
页数：1
相关论文
共 50 条
  • [41] Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
    Pariser, David
    Frankel, Ellen
    Schlessinger, Joel
    Poulin, Yves
    Vender, Ronald
    Langley, Richard G.
    Meng, Xiangyi
    Guana, Adriana
    Nyirady, Judit
    DERMATOLOGY AND THERAPY, 2018, 8 (01) : 17 - 32
  • [42] Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
    David Pariser
    Ellen Frankel
    Joel Schlessinger
    Yves Poulin
    Ronald Vender
    Richard G. Langley
    Xiangyi Meng
    Adriana Guana
    Judit Nyirady
    Dermatology and Therapy, 2018, 8 : 17 - 32
  • [43] Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study
    Luigi Gargiulo
    Luciano Ibba
    Giulia Pavia
    Carlo Alberto Vignoli
    Francesco Piscazzi
    Mario Valenti
    Federica Sanna
    Chiara Perugini
    Jessica Avagliano
    Antonio Costanzo
    Alessandra Narcisi
    Dermatology and Therapy, 2022, 12 : 2309 - 2324
  • [44] Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study
    Gargiulo, Luigi
    Ibba, Luciano
    Pavia, Giulia
    Vignoli, Carlo Alberto
    Piscazzi, Francesco
    Valenti, Mario
    Sanna, Federica
    Perugini, Chiara
    Avagliano, Jessica
    Costanzo, Antonio
    Narcisi, Alessandra
    DERMATOLOGY AND THERAPY, 2022, 12 (10) : 2309 - 2324
  • [45] Real-World Effectiveness and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis in Adult Patients: A 52-Week Multicenter Retrospective Study
    Yeung, Jensen
    Sood, Siddhartha
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2024,
  • [46] Bimekizumab for the treatment of genital, scalp, and nail psoriasis: A 52-week real-world study
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    JOURNAL OF DERMATOLOGY, 2024,
  • [47] Improvement in touch avoidance in patients with genital psoriasis treated with ixekizumab: 52-week results of a phase 3 clinical trial in patients with moderate-to-severe genital psoriasis (IXORA-Q)
    Soung, Jennifer
    Cather, Jennifer Clay
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB69 - AB69
  • [48] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial
    Bissonnette, R.
    Iversen, L.
    Sofen, H.
    Griffiths, C. E. M.
    Foley, P.
    Romiti, R.
    Bachinsky, M.
    Rottinghaus, S. T.
    Tan, H.
    Proulx, J.
    Valdez, H.
    Gupta, P.
    Mallbris, L.
    Wolk, R.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 37 - 37
  • [49] Predictors of response to tofacitinib or etanercept in a phase 3 randomized, noninferiority study in patients with moderate to severe chronic plaque psoriasis
    Lambert, Jo
    Strohal, Robert
    de la Cruz, Claudia
    Thaci, Diamant
    Bachelez, Herve
    Iversen, Lars
    Rottinghaus, Scott
    Tallman, Anna
    Tan, Huaming
    Berstein, Gabriel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB263 - AB263
  • [50] Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis
    Fan, Wen
    Lei, Na
    Zheng, Yujie
    Liu, Juan
    Cao, Xuechen
    Su, Ting
    Su, Zhonglan
    Lu, Yan
    SCIENTIFIC REPORTS, 2024, 14 (01):
12345